Pacira BioSciences Receives US Patent for Exparel Composition

MT Newswires Live12-04

Pacira BioSciences (PCRX) said Tuesday it obtained a patent from the US Patent and Trademark Office protecting the chemical composition of its non-opioid pain treatment Exparel into July 2044.

Pacira said it will submit the patent for listing in the Food and Drug Administration's Orange Book, or Approved Drug Products with Therapeutic Equivalence Evaluations.

The company said it intends to file a patent infringement lawsuit against Jiangsu Hengrui Pharmaceuticals and its US distributor, Fresenius Kabi USA.

Jiangsu Hengrui Pharmaceuticals and Fresenius Kabi USA didn't immediately respond to requests for comment from MT Newswires.

Pacira shares were down 2.7% in recent Tuesday trading.

Price: 17.33, Change: -0.48, Percent Change: -2.72

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2488940410?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-04 00:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488940410","market":"nz","top_or_hot":-1,"title":"Pacira BioSciences Receives US Patent for Exparel Composition","media":"MT Newswires Live","content":"<html><body><p> Pacira BioSciences (PCRX) said Tuesday it obtained a patent from the US Patent and Trademark Office protecting the chemical composition of its non-opioid pain treatment Exparel into July 2044.</p><p>Pacira said it will submit the patent for listing in the Food and Drug Administration's Orange Book, or Approved Drug Products with Therapeutic Equivalence Evaluations.</p><p>The company said it intends to file a patent infringement lawsuit against Jiangsu Hengrui Pharmaceuticals and its US distributor, Fresenius Kabi USA.</p><p>Jiangsu Hengrui Pharmaceuticals and Fresenius Kabi USA didn't immediately respond to requests for comment from MT Newswires.</p><p>Pacira shares were down 2.7% in recent Tuesday trading.</p><p>Price: 17.33, Change: -0.48, Percent Change: -2.72</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pacira BioSciences Receives US Patent for Exparel Composition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPacira BioSciences Receives US Patent for Exparel Composition\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-04 00:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pacira BioSciences (PCRX) said Tuesday it obtained a patent from the US Patent and Trademark Office protecting the chemical composition of its non-opioid pain treatment Exparel into July 2044.Pacira ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2488940410","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488940410","pubTimestamp":1733243429,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Pacira BioSciences  said Tuesday it obtained a patent from the US Patent and Trademark Office protecting the chemical composition of its non-opioid pain treatment Exparel into July 2044.Pacira said it will submit the patent for listing in the Food and Drug Administration's Orange Book, or Approved Drug Products with Therapeutic Equivalence Evaluations.The company said it intends to file a patent infringement lawsuit against Jiangsu Hengrui Pharmaceuticals and its US distributor, Fresenius Kabi USA.Jiangsu Hengrui Pharmaceuticals and Fresenius Kabi USA didn't immediately respond to requests for comment from MT Newswires.Pacira shares were down 2.7% in recent Tuesday trading.Price: 17.33, Change: -0.48, Percent Change: -2.72","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","PCRX":"Pacira Pharmaceuticals"},"translate_title":"Pacira BioSciences获得Exparel组合物美国专利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PCRX":0.9},"content_text":"Pacira BioSciences (PCRX) said Tuesday it obtained a patent from the US Patent and Trademark Office protecting the chemical composition of its non-opioid pain treatment Exparel into July 2044.Pacira said it will submit the patent for listing in the Food and Drug Administration's Orange Book, or Approved Drug Products with Therapeutic Equivalence Evaluations.The company said it intends to file a patent infringement lawsuit against Jiangsu Hengrui Pharmaceuticals and its US distributor, Fresenius Kabi USA.Jiangsu Hengrui Pharmaceuticals and Fresenius Kabi USA didn't immediately respond to requests for comment from MT Newswires.Pacira shares were down 2.7% in recent Tuesday trading.Price: 17.33, Change: -0.48, Percent Change: -2.72","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2488940410"}